AFT Pharmaceuticals advises of the release yesterday evening by the High Court at Auckland of its judgment upholding in part claims by PBL Solutions Limited (PBL) against AFT, and dismissing others.
AFT Orphan Pharmaceuticals judgment
Read More
News
Retirement of Jon Lamb
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Jon Lamb has announced his intention to retire as a director of the company, following the recruitment and appointment of a replacement independent director to the Board. Chair David Flacks said: “On behalf of the Board I would like to extend my thanks to Jon for his outstanding service […]
Read More
AFT Pharmaceuticals 2023 Annual Meeting
Annual Meeting Overview
Read More
Notice of Annual Meeting of Shareholders 2023
June 30th 2023 Notice is hereby given that the Annual Meeting of shareholders of AFT Pharmaceuticals Limited (AFT or the Company) will be held at the Milford Cruising Club, 24 Craig Road, Milford, Auckland, New Zealand, on Friday, 4 August 2023 commencing at 10.30am (New Zealand time). Agenda A) Addresses Our Chairman, David Flacks, and […]
Read More
Financial Results 2023: AFT declares maiden dividend; record revenue
Financial Results for the 12 Months to 31st of March 2023
Read More
AFT Pharmaceuticals to announce full year results on Monday May 22 2023
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release on Monday May 22 2023 its full year results for the year ended March 31 2023.
Read More
AFT licenses Maxigesic® IV in the US
AFT Pharmaceuticals announces it has signed an exclusive License and Distribution Agreement with Hikma Pharmaceuticals USA (“Hikma”) for the commercialisation of its Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine, in the United States.
Read More
AFT licenses Pascomer for Europe
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed a new commercialisation and development agreement for its orphan drug Pascomer®
Read More
Maxigesic® IV licensed in eight new European markets
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed an exclusive Maxigesic® IV licensing agreement for eight new European markets.
Read More
AFT confirms demonstration of 24-hour efficacy for Crystawash extend hand sanitiser
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces independent laboratories have found that its new Crystawash Extend Hand Sanitiser
Read More
AFT builds North American momentum
Diversified pharmaceutical company appoints new north American-based director and launches Maxigesic® in Canada.
Read More
Management financial discussion and analysis for the half year to 30 September 2020
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces continued growth in revenue and normalised earnings as it benefits from growth across its portfolio
Read More
Financial results for half year ended 30 September 2020
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces continued growth in revenue and normalised earnings as it benefits from growth across its portfolio.
Read More
AFT opening European office, signs new partners for maxigesic iv and oral range
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) announces the establishment of a new subsidiary in Ireland
Read More
AFT welcomes us fda complete response letter
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has received a US Food and Drug Administration (FDA) complete response letter (CRL).
Read More
AFT appoints Anita Baldauf as a director
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) has today appointed Anita Baldauf as a non-executive director.
Read More
AFT and Setek sign supply agreement
Agreement covers pharmaceutical-grade medicinal cannabis ingredients for products initially targeted for Australia and New Zealand
Read More
Maxigesic IV® distribution deals signed in UK and Hong Kong
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) has signed exclusive Maxigesic IV® distribution and supply agreements for the UK and Hong Kong, with the company targeting sales of the medicine in these territories in 2022.
Read More